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Summary 
 
Huntingtin associated protein-1 (HAP1) is a novel protein found in the 
patient of Huntington’s disease. Some reports show that it might act as a 
scaffold in the assembly of protein complexes and participate in 
intracellular trafficking. Furthermore, there is evidence that HAP1 is 
expressed in pancreatic islet β-cells.  
 
In my project, I knocked down the HAP1 expression by RNAi technique in 
INS-1 cells (a insulin secreting cell line from rat insulinoma). In insulin 
secretion experiment, the knockdown cells secreted less insulin upon the 
stimulation by high concentrations of glucose compared with the control 
cells treated with scramble siRNA. In addition, high KCl-induced insulin 
secretion was also inhibited. However, my results indicated that HAP1 
knockdown did not affect glucose metabolism and, glucose-induced 
membrane potential depolarization and intracellular Ca2+ elevation. On the 
other hand, HAP1 knockdown reduced INS-1 cell growth and affected cell 
cycle by arresting them at G2/M phase. However, apoptosis was not 
induced by HAP1 knockdown in INS-1 cells. 
 
Thus, it can be concluded that HAP1 knockdown not only reduced glucose-
stimulated insulin section by interfering with the step beyond [Ca2+]i rise in 
the secretion process cascade, but also slowed down the growth of INS-1 
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cells without induction of apparent apoptosis. These data suggest that 
HAP1 may participate in the regulation of insulin secretion and growth of 
pancreatic islet β-cells.  
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ABBREVIATIONS  
All abbreviations definitions show at their first appearance in the text and 
some frequently used abbreviations are also listed as following: 
 
Ac-CoA acetyl-coenzyme A 
AMP adenosine 3’ –monophosphate 
ATP adenosine 5’ –triphosphate 
BSA bovine serum albumin 
[Ca2+]i cytoplasmic free Ca2+ concentration 
cAMP adenosine 3’, 5’ –cyclic monophosphate, cyclic AMP 
Caspase Cysteine-requiring Aspartate protease 
DAG diacylglycerol 
DEPC diethyl pyrocarbonate 
DMSO dimethyl sulphoxide 
DPBS Dulbecco’s phosphate buffered saline 
DNA deoxyribonucleotide acid 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
EGTA ethylene glycol-bis(beta-aminoethyl ether)-N,N,N’,N’-
teraacetic acid 
 
FACS fluorescence-activated cell sorting 
FITC fluorescein-5-isothiocyanate 
GLP glucagons-like peptide 
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Glut2 glucose transporter-2 
GSIS glucose stimulated insulin secretion 
GTP guanosine triphosphate 
HEPES N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] 







NADPH nicotinamide adenine dinucleotide phosphate 
PA phosphatidic acid 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate-buffered saline 
PI phosphatidylinositol 
PKA cAMP dependent protein kinase 
PMS phenazine methosulfate 
PMSF phenylmethylsulfonyl fluoride 
PVDF polyvinylidene difluoride 
RER rough endoplasmic reticulum 
RISC RNA induced silencing complex 
RNA ribonucleotide acid 
RNAi RNA interference 
RRP ready releasable pool 
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SDS sodium dodecyl sulphate 
shRNA short hairpin RNA 
siRNA short interference RNA 
SNARE soluble N-ethylmaleimide-sensitive factor attachment 
protein receptor 
 
TBS tris-buffered saline 
TBS-T TBS with 0.5% Tween-20  
T1DM Type 1 diabetes mellitus 
T2DM Type 2 diabetes mellitus 
TEMED N,N,N’,N’-tetra methylthylene diamine 
VAMP vesicle-attached membrane protein 
 
 








1.1 β-cell and insulin secretion 
 
1.1.1 Diabetes mellitus 
 
Diabetes mellitus is a metabolic syndrome which causes systemic 
microvascular diseases, especially in heart, eye and kidney. Diabetes 
mellitus is the third most critically chronic disease after cardiovascular 
disease and cancer. It was estimated by World Health Organization (WHO) 
that there was 220 million diabetes patients worldwide in 2009 [1, 2]. 
Diabetic patients show a chronic hyperglycemia and insulin deficiency. So 
far, two main types of diabetes mellitus are classified [3]: Type 1 diabetes 
and Type 2 diabetes. Patients with type 1 diabetes cannot produce insulin 
by themselves, thus have to inject insulin substitute to maintain glucose 
homeostasis. On the other hand, type 2 patients result from relative insulin 
deficiency and insulin resistance, in which cases, cells cannot properly use 
insulin [3].  
 
Pancreatic β-cells, which produce and secrete insulin, play a key role in the 
development of diabetes mellitus. Although two types of diabetes have 
different onset mechanisms, the common part in their pathology is the 
insulin secretion dysfunction. In type 1 diabetes, T-lymphocyte-mediated 
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autoimmune attack and destroys β-cells, which fail to release insulin. In 
contrast, insulin resistance is the main factor for the development of type 2 
diabetes. Besides, insulin deficiency is also considered as a key etiological 
cause. Absolute insulin deficiency means that β-cells are destroyed by 
hyperglycemia [4-6], and the total number of β-cells is decreased; however, 
relative insulin deficiency refers to the fact that insulin fails to take action 
properly in the cells and the insulin receptors cannot correctly carry on the 
subsequent signaling cascade triggered by insulin. As a result, two types of 




Insulin is a 51 amino acid hormone produced and secreted by the β-cells in 
the Islets of Langerhans in pancreas [10]. Insulin consists of two chains (A 
and B) linked together by disulfide bonds. In the secretory granules of β-
cells, insulin is stored in the inactive and stable hexamer form, while the 
active form is the monomer form [11]. The amino acid sequence of insulin 
is greatly conserved among animals.  Insulin from other mammals thus is 
biologically active in human beings. This is the applicable basis to facilitate 
insulin extracted from other species, such as porcine insulin, to treat 
diabetic patients in the early days [12].  Insulin regulates a series of other 
cellular activities, such as protein and fat synthesis, RNA and DNA 
synthesis, as well as cell growth and differentiation. One of its main 
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functions is the promotion of glucose uptake from the systemic circulation 
into target tissues such as liver, muscles and adipose [13].  
 
Glucose and other nutrients can enhance insulin expression in transcription 
and translation level. Insulin gene transcription is regulated by many 
transcription factors, such as, Pdx1, NeuroD, MafA and so on [14, 15]. The 
product of insulin gene transcription is preproinsulin mRNA. The 
preproinsulin carries a signal peptide, which facilitates preproinsulin to 
enter rough endoplasmic reticulum (RER) lumen. Consequently, the signal 
peptide is hydrolyzed and the proinsulin is properly folded . After this, 
proinsulin is transported to the Golgi apparatus where the disulfide bonds 
between A chain and B chain are formed after a connection peptide in the 
middle region is removed by prohome convertases. The mature insulin and 
equimolar C-peptide is enveloped in secretory granules ready for secretion 
upon stimulation of β-cells [16, 17].  
 
1.1.3 Insulin secretion 
 
The insulin secretion response to the elevation of extracellular glucose 
concentrations is a sigmoid relationship. There is no apparent influence on 
insulin secretion if glucose concentration is below about 3 mM. With the 
increase of glucose from 4 to 17 mM, the physiological range [18, 19], the 
	   5	  
largest insulin secretion occurs. However, the insulin secretion seems to 
attain a plateau even with higher glucose stimulation [20].  
 
A biphasic insulin secretion pattern is observed in pancreatic β-cells upon 
the stimulation by an increase of glucose concentrations [21, 22]. In 
isolated rat islets, a rapid and transient increase of insulin secretion (first 
phase) arise briefly 1 to 2 min later after the stimulation. The increase of 
secretion rate reaches a peak 2 min later, and declines to the bottom at 
time point of 8 min. After this, a slow but sustained secretion (second 
phase) reaches a plateau after about 36 min [23].  
 
A complex network of signaling pathways is involved in the glucose-
stimulated biphasic insulin secretion [23-25]. With the assistance of 
glucose transporter-2 (Glut2), glucose diffuses into β-cells and is 
phosphorylated by glucokinase, followed by metabolism through glycolysis 
and mitochondrial oxidation via the citric acid cycle. This leads to the 
increase of cellular ATP/ADP ratio, resulting in the close of ATP-sensitive 
K+ (KATP) channels and depolarization of membrane potential of cells. 
Consequently, the voltage-dependent Ca2+ channels are opened and a rise 
of intracellular free Ca2+ levels ([Ca2+]i) ensues, which triggers insulin 
release via exocytosis of granule fusion with the plasma membrane. On the  
other hand, the KATP channel-independent pathways potentiate the Ca2+-
mediated secretory process  [26]. Furthermore, there is evidence 
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supporting that the KATP channel-independent pathway of glucose 
metabolism is responsible for the second phase of glucose-stimulated 
insulin secretion. However, the underlying mechanism remains to be 
elucidated.  
 
Figure 1. The classic signaling pathway for insulin secretion from β-cells 
 
Insulin-containing granules are located in two different pools [27]: docked 
pool and reserve pool. The granules in the reserve pool are larger than the 
docked granules. The granules in the docked pool convert between several 
states for the rapid first phase release. They may be in the primed, readily 
releasable and immediately releasable status. Upon the stimulus of [Ca2+], 
exocytosis occurs. Once the docked granules are discharged, the granules 
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in the reserve pool are activated and translocated to the docked pool for 
the sustained second phase release.  
 
There are many other physiological and pharmacological regulators for 
insulin secretion besides glucose [28]. Generally, they are classified into 
three categories: initiators, potentiators and inhibitors. The initiators can 
initiate insulin secretion on their own. Some fatty acids and amino acids 
may act in this way. Sulphonylureas, such as tolbutamide and 
glibenclamide, are potent KATP-channel blocker and thus are used for 
clinical treatment of type 2 diabetes [29, 30]. The potentiators cannot 
trigger the insulin release, but they are able to strengthen the already 
activated secretion process. Forskolin, for instance, is usually used to raise 
levels of cyclic AMP (cAMP) which activates protein kinase A (PKA) [31]. 
The latter can potentiate the insulin secretion. Glucagon and glucagon-like 
peptide 1 increase glucose-stimulated insulin secretion also in this manner  
[32]. Conversely, the inhibitors block the process of insulin secretion. They 
affect the K+ and Ca2+ channels or prevent the exocytosis of insulin 
granules. For example, diazoxide is an ATP-sensitive K+ channel activator, 
which can be used to inhibit insulin secretion in insulinoma patient [33]. 
And, some neurotransmitters and hormones belong to this group, such as 
adrenalin and somatostatin.  
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1.1.4 insulin-secreting cell model 
 
The availability of great amount and stable insulin-secreting cells is 
essential for the research in diabetes and β-cell biology. The isolation of a 
considerable number of β-cells from pancreatic islets is time-consuming 
and laborious. Additionally, the β-cells from islets cannot maintain a stable 
culture for a long period. And their ability to synthesize insulin rapidly 
declines in vitro. Therefore, dozens of insulin-secreting cell lines have been 
created by induced insulinomas, viral transformation, and transgenic mice 
[34]. Among them, the INS-1 cell line from rat insulinoma is a most widely-
used cell line [35]. INS-1 cells display many aspects of primary β-cells 
including morphological characteristics typical of native β-cells, high insulin 
content, response to glucose stimulation, Ca2+ mediated exocytosis and so 
on. Thus, INS-1 cells are widely used as a paradigm to study diabetes and 
insulin secretion. 
 
1.1.5 β-cell growth and cell cycle 
 
It is generally accepted that β-cell mass is dynamic and oscillates both in 
function and mass to sustain the glucose level within a restricted 
physiological range [36]. The changes involve with individual cell volume, 
cell replication and neogenesis, and cell death rate [37]. Mature β-cells 
have very weak ability to proliferate and are readily replaced when 
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destroyed. An increase of β-cell growth may occur in certain 
circumstances, e.g. after new born, pancreatectomy, or in pregnancy.    
 
In T2DM patients, data shows that there is compensatory growth of β-cell 
mass at the early stage due to the insulin dysfunction and insulin 
resistance [38]. There are two ways to maintain the normal glucose level: to 
produce and secrete more insulin, or  to increase beta-cell mass [36, 39]. 
The β-cell mass are reported to be maintained by either replication of pre-
existing β-cell or neogenesis of precursor cells from the pancreatic duct. 
The increase of β-cell mass includes not only hyperplasia (cell number 
increase), but also hypertrophy (cell volume increase).   
 
Sustained elevated glucose levels can initiate the disorders of insulin 
biosynthesis and secretion, and finally lead to β-cell death. This is noted as 
glucotoxicity [40]. The increase of glucose concentration is a double edged 
sword. In a short term, it can promote islets to enhance insulin secretion 
and β-cell proliferation; but the prolonged exposure to high glucose can 
lead to hindered insulin secretion and even β-cell apoptosis [41].  
 
Normal cell replication and growth are regulated by the precise control of 
entry, passage, and departure through the cell cycle [42, 43]. The process 
is activated by the complicated regulation of cyclins and cyclin-dependent 
kinases (e.g. Cdk4 or Cdk6). Among them, cyclin D1 together with Cdk4 
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plays a key role in β-cell proliferation. The loss of Cdk4 expression in Cdk4-
/- mice affected pancreas development and led to the reduced islet mass. In 
addition, Cdk4-/- mice displayed the characteristics of insulin deficient 
diabetes. Besides, β-cell division is regulated by growth factors, mitogens, 
and various intracellular signaling pathways including cAMP/PKA, 
PI3K/Akt, JAK/STAT and Wnt/GSK. 
  
To ensure the fidelity of cell division, cell cycle checkpoints verify each 
phase to validate their complete preparation to enter into next phase. One 
of the most important roles of checkpoints is to control DNA damage. Cells 
with DNA damage either are repaired to step into next phase or induced to 
apoptosis. There are three cell cycle checkpoints in eukaryotes: G1 




1.2.1 HAP1 background 
 
Huntington’s disease (HD) is an autosomal dominant neurodegenerative 
disorder, which is characterized by uncontrolled movement, psychiatric 
disturbance, and cognitive impairment [44-46]. The disease is caused by 
expansion of a polyglutamine (polyQ) domain at the N-terminus of a large 
protein called mutant Huntingtin. Huntingtin is expressed in many tissues in 
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the body, with the highest levels in the brain, and usually the repeated 
polyQ sequence is below 36. Huntingtin is a ubiquitous protein important 
for neuronal transcription, development, and survival. A sequence of 36 or 
more polyQ alters the interaction of Huntingtin with other proteins and 
accelerates the decay of some neurons, which leads to the pathogenesis of 
Huntington's disease [47, 48]. 
 
Among all the proteins which interact with Huntingtin, Huntingtin associated 
protein-1 (HAP1) was the first to be identified and has been studied 
extensively [47, 49, 50]. HAP1 was identified by a yeast two-hybrid screen 
using a rat brain cDNA library. HAP1 has neither conserved 
transmembrane domains nor nuclear localization signals, which shows it is 
a cytoplasmic protein.  HAP1 contains several coiled–coiled domains in the 
middle region and multiple N-myristoylation sites, which are expressed in 
quite a few proteins that are associated with membrane proteins and 
involved in vesicular trafficking.  
 
HAP1 has an extensive distribution within neurons including cell bodies, 
axons, dendrites, and so on. Subcellular fractionation studies indicate that 
HAP1 is present in both soluble and membrane-containing fractions and 
enriched in nerve terminal vesicle-rich fractions [47, 51, 52]. Consistently, 
electron microscopy studies show that HAP1 is associated with 
microtubules and many types of membranous organelles, including 
	   12	  
mitochondria, endosomes, multivesicular bodies, lysosomes, and synaptic 
vesicles [52]. 
 
HAP1 has been found in several species including rat, mouse, and human 
[50]. Furthermore, there are two isoforms in rat, HAP1 isoform A (HAP1A) 
and HAP1 isoform B (HAP1B), which differ at their C-terminals.  One 
human HAP1 isoform has been characterized that shares great similarity 
with rat HAP1A [53, 54]. 
 
1.2.2 HAP1 function 
 
Although the precise function of HAP1 is still unknown, increasing evidence 
shows that it might play a crucial role in the intracellular vesicle trafficking 
[55-57]. HAP1 not only interacts with molecular motors, which are required 
in the intracellular transport of membrane organelles, but also is involved in 
the endocytic trafficking of membrane receptors. Furthermore, A recent 
report shows that one of HAP1 receptors in the hypothalamus is associated 
with the control of food intake and body weight, which is involved in the 
feeding-inhibitory actions of insulin in the brain [58]. 
 
p150Glued is the largest member of all the dynactin subunits. Dynactin is a 
multisubunit protein complex that binds to dynein, which is the microtubule 
motor participating in retrograde transport in cells. HAP1 binds to p150Glued 
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and induces the microtubule-dependent retrograde transport of 
membranous organelles. Kinesins are the largest superfamily of 
microtubule-dependent motors for anterograde transport. Kinesin light 
chain (KLC) is involved in protein-protein interactions and thought to 
regulate motor activity and binding to different cargoes. HAP1 was found to 
interact with KLC that drives anterograde transport along microtubules in 
neuronal processes [59].  
 
Hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs) is 
involved in the endosome-to-lysosome trafficking and interacts with 
HAP1[60]. HAP1 co-localizes with Hrs on early endosomes. 
Overexpression of HAP1 causes the formation of enlarged early 
endosomes, inhibits the degradation of internalized epidermal growth factor 
receptors, but, does not affect either constitutive or ligand-induced 
receptor-mediated endocytosis. These findings implicate that HAP1 and its 
interacting proteins potently block the trafficking of endocytosed EGF 
receptors from early endosomes to late endosomes. 
 
ϒ-Aminobutyric acid type A receptors (GABAARs) are the major sites of fast 
synaptic inhibition in the brain. In neurons, rapid constitutive endocytosis of 
GABAARs is evident. Internalized receptors are then either rapidly recycled 
back to the cell surface, or on a slower time scale, targeted for lysosomal 
degradation. GABAAR endocytic sorting is an essential determinant for the 
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efficacy of synaptic inhibition. HAP1 may modulate synaptic GABAAR 
number by inhibiting receptor degradation and facilitating receptor 
recycling, which suggests a role for this protein in the construction and 
maintenance of inhibitory synapese [58, 61, 62]. 
 
Tropomyosin-related kinase A receptor tyrosine kinase (TrkA), is a nerve 
growth factor receptor whose internalization and trafficking are required for 
neurite outgrowth. HAP1 knockdown by RNA interference reduces neurite 
outgrowth and the level of TrkA. HAP1 maintains the normal level of 
membrane TrkA by preventing the degradation of internalized TrkA. These 
findings suggest that HAP1 trafficking is critical for the stability of TrkA and 
neurite growth [63]. 
 
HAP1 has been known as a vital component of the stigmoid body (STB) 
and recently informed to play a protective role against neurodegeneration 
in Huntington’s disease [64]. HAP1 interacts with androgen receptor (AR) 
through its ligand-binding domain in a polyQ-length-dependent manner and 
forms prominent inclusions sequestering polyQ-AR, which is derived from 
spinal-and-bulbar-muscular-atrophy (SBMA). Addition of 
dihydrotestosterone reduces the association strength of HAP1 with ARQ25 
(normal) more dramatically than that with ARQ65 (abnormal). Thus, the 
SBMA-mutant ARQ65-induced apoptosis is suppressed by co-transfection 
with HAP1. 
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HAP1 gene disruption experiment in mice demonstrates that HAP-1 plays 
an essential role in regulating postnatal feeding [61, 65, 66]. HAP1 is richly 
expressed in the hypothalamus, which is known to regulate feeding 
behavior[58]. Mice with homozygous HAP1 disruption did not change the 
expression of Huntingtin, the interacting partner of HAP1. However, the 
HAP1(-/-) pups showed decreased feeding behavior that eventually results 
in malnutrition, dehydration and premature death [67].  
 
Immunofluorescence confocal microscopy of dividing striatal hybrid cells 
showed that HAP-1 immunoreactivity was highly expressed throughout the 
cell cycle [51]. HAP-1 localized to the mitotic spindle apparatus, especially 
at spindle poles and on vesicles and microtubules of the spindle body. 
Those evidences suggest that HAP-1 play a role in vesicle trafficking and 
organelle movement in mitotic cells.  
 
1.2.3 HAP1 distribution in the β-cells of pancreatic islets 
 
Initial studies showed that HAP1 was expressed in the central nervous 
system, especially in the hypothalamus [47, 52, 68]. Later, Dragatsis et 
al.[63] showed that, in adult mice, Hap1 expression was detected not only 
in the brain but also in the ovary, testis, and the intermediate lobe of the 
pituitary by northern analysis and hybridization histochemistry [69]. Based 
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on functional similarity between neuron and endocrine cell in vesicular 
trafficking, Liao and his colleagues [70] have examined the expression and 
localization of HAP1 in most the rat endocrine organs by 
immunohistochemistry. In pancreatic islets, moderate HAP1 
immunoreactivity was discovered [71]. They were scattered throughout the 
islets and localized in the cytoplasm. Conversely, the exocrine portion of 
the pancreas did not contain any HAP1-immunoreactive product.  
 
Further study of HAP1 expression in rat islets by double immunofluorescent 
staining [71] has showed that HAP1 is selectively expressed in the insulin-
immunoreactive β-cells but not in α-cells and δ-cells. Less than 80% 
isolated rat pancreatic islet cells express both HAP1 and insulin.  HAP1 is 
also expressed in INS-1 cell line, a commonly-used insulin-secreting cell 
line from rat insulinoma. Western blotting further confirms that there are two 
HAP1 isoforms in INS-1 cells and isolated rat pancreatic islets, which are 
the same sizes as those in the brain.  
 
1.3 Aims and significance of this study 
 
Diabetes mellitus is one of the most epidemic metabolic diseases in the 
world. Both type 1 and types 2 diabetes involve the insulin deficiency. 
Thus, the research on insulin and its secretion has been a hot topic since 
its discovery. The signaling pathways for controlling insulin secretion are 
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quite complex because of the implication of a series of intracellular 
trafficking processes with participation of many partners. Although some of 
the events and cascades in the underlying mechanisms have been 
mapped, for example, KATP channels, a lot of unknown in this field need 
further exploration.  
 
HAP1 is a protein found in the nervous system but also expressed in the 
insulin-secreting β-cells. It is recognized that HAP1 may play a role in 
intracellular trafficking of vesicles. Therefore, the aim of this project is to 
explore the potential role of HAP1 in insulin-secreting cells after knockdown 
of its expression in INS-1 cell line. The findings of HAP1 role in INS-1 cell 
may shed light on the understanding of complicated signaling pathways 
regulating insulin secretion in β-cells. 
 
HAP1 is a relatively novel protein first discovered in 1993 and universally 
expressed in the nervous system in the patients of Huntington’s disease. 
So far, there is no established mechanism or theory to define its function. 
Many functional descriptions of HAP1 are based on the limited 
observations in certain nervous cells. One study in 2005 reported that 
transgenic mouse model of Huntington’s disease is liable to develops 
diabetes due to deficient β-cell mass and exocytosis [72]. This suggests 
that HAP1 may be in both diabetes mellitus and Huntington’s disease. 
Since neurons and endocrine cells share some similar features in their 
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function to some extent [73, 74], the study on HAP1 in diabetes may 
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CHAPTER 2 
MATERIALS AND METHODS 




Table 1. Materials and their involving experiments 
Experiments and procedures Materials 
INS-1 cell culture media 1. 10.4 g/L RPMI1640 (Sigma) 
2. 10% FBS 
3. 1 mM sodium pyruvate and 50 μM 2-
mercaptoechanol 
4. 25 μg/ml ciprofloxacin hydrochloride 
5. 10 mM HEPES, pH7.2~7.3 
 
INS-1 cell storage media 1. 10.4 g/L RPMI1640 (Sigma) 
2. 20% FBS 
3. 7% DMSO 
HAP1 siRNA transfection  1. Lipofectamine 2000 (Invitrogen) 
2. HAP1 siRNA oligo 
3. Scrambled siRNA 
4. INS-1 culture media without antibiotics 
 
RNA extraction 1. 70% ethanol 
2. RLT buffer 
3. RW1 buffer 
4. RPE buffer 
5. RNase-free buffer 
 
cDNA preparation 1. DEPC water 
2. 5× Reaction Mix  
3. Maxima enzyme Mix 
4. RNA template 
 
SYBR green real-time PCR 1. DEPC water 
2. 500 μg/μl cDNA 
3. 2× SYBR Master Mix 
4. HAP1 primers 
 
Protein extraction        Lysis buffer: 0.1mM PMSF, 150 mM NaCl, 1 
mM EDTA, 50 mM Tris-HCl, and 10 μg/ml each of 
pepstaitin, aprotinin, and leupeptin  
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Protein measurement 1. Coomassie Brilliant Blue R-250 
2. 500 μg/ml standard protein 
Western Blotting 1. Loading buffer: 4× DualColorTM protein 
loading buffer and 20× Reducing Agent Dtt 
(Thermo Scientific) 
2. Kaleidoscope prestained standard 
molecular weight marker (Bio-Rad) 
3. Tank buffer: 0.025 mM Tris, 0.192 M 
glycine, 0.1% SDS, pH 8.3 
4. Semi-dry buffer: 250 mM glycine, 25 nM 
Tris, and 15% methanol 
5. TBS-T buffer: 0.2% Tween-20, 20 mM Tris-
HCl, pH 7.5, and 150 mM NaCl 
 
DNA content measurement 1. 200 μg/ml standard DNA 
2. 1 μg/ml Hoechst 33258 (Sigma) in 0.05 M 
Na2HPO4 and 2.0 M NaCl 
3. Dilution buffer, 0.05M Na2HPO4 and 2.0 M 
NaCl 
 
MTS test  1. MTS 
2. PMS solution 
3. 1 M glucose 
4. 1 μM forskolin 
5. 1× PBS 
 
Propidium iodide (PI) staining 1. 70% ethanol 
2. 1×PBS 
3. PI solution: 1×PBS containing 0.1% triton 
X-100, 0.2 mg/ml RNase A, 20 μg/ml PI 
 
Insulin secretion 1. KRBH buffer: 124 mM NaCl, 2.5 mM 
CaCl2, 5.6 mM KCl, 1.2 mM MgSO4, and 
20 mM Hepes, pH7.4 
2. Glucose stock: 1 M 
3. Forskolin: 1 μM 
4. Tolbutamide: 0.1 M 
5. IBMX: 0.1 M 
6. KCl stock: 3.4 M 
7. RIA assay buffer: 0.05 M phosphosaline, 
0.025 M EDTA, 0.08% sodium azide, and 
1% BSA 
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Rat insulin 
radioimmunoassay 
1. Assay buffer: 0.05 M phosphosaline, 0.025 
M EDTA, 0.08% sodium azide, and 1% 
BSA 
2. Rat insulin antibody (RIA kit from Millipore) 
3. 125I-Insulin 
4. Rat insulin standard: 0.1, 0.2, 0.5, 1.0, 2.0, 
5.0, 10.0 ng/mL 
5. Precipitating reagent: goat anti-guinea pig 
IgG serum, 3% PEG and 0.05% Triton X-
100 in 0.05 M phosphosaline, 0.025M 




1. KRBH buffer 
2. Bisoxonol stock: 100 mM 
3. Glucose: 1 M 
4. KCl: 3.4 M 




1. KRBH buffer 
2. Fura-2/AM: 1 M 
3. Glucose: 1 M 
4. KCl: 3.4 M 




1. 17 megohm water 
2. Caspase 3 assay buffer: 20 mM HEPES, 
pH 7.4, with 2 mM EDTA, 0.1% CHAPS, 
and 5 mM DTT 
3. Caspase 3 substrate (Ac-DEVD-AMC) 
solution: 10 mM in DMSO 
4. Reaction Mixture: 16.7 μM Ac-DEVD-AMC 
in caspase 3 assay buffer 
5. AMC standard: 100 nM, 500 nM, 1 μM, 2 
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2.2 Methods 
 
2.2.1 INS-1 cell culture and storage 
 
INS-1 cells from passages 65-85 were utilized in this study. The culture 
media for INS-1 cells consist of RPMI 1640 solution, 10% fetal bovine 
serum (v/v), 10 mM HEPES, 25 μg/ml ciprofloxacin hydrochloride, 50 μM 2-
mercaptoethanol and 1 mM pyruvate as described [75]. INS-1 cells were 
seeded in culture flasks or multi-well plates at a concentration of 1×106/ml 
and kept in an incubator at 37˚C with humidified air containing 5% CO2. 
The media were replaced every 3 or 4 days. Regularly, the cells were 
subcultured weekly by trypsinization. Upon subculture, media were 
discarded and cells were rinsed with 37˚C phosphate-buffered saline 
solution (PBS). Subsequently, 0.025% trypsin were added to cover the 
bottom of the containers and incubated for less than 5 min. As soon as 
most cells detached from the bottom of vessels, ice-cold INS-1 media 
containing 10% serum were added to terminate the trypsinization. 
Afterwards, the cell suspension was centrifuged at 130× g for 5 min at 
room temperature to obtain cell pellet. After resuspended in warm INS-1 
media, the cell number was counted before subculture or seeding.  
 
For long term storage, INS-1 cells at a concentration of 5×106/ml were 
added in the 1 ml cryovial. The conservation solution was freshly made with 
RPMI 1640 solution, 20% FBS, and 7% DMSO. After a slowly and 
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progressively decrease of temperature, cryovials were stored in -150˚C 
refrigerator. When younger cells were required for experiments, stored INS-
1 cells were thawed to meet the needs. Cryovials were put in 37˚C water 
bath tank till completely thawed. Afterwards, cells were washed with INS-1 
media once. After centrifuge, cell pellets were resuspended in culture 
media and seeded into flasks. Media were changed on the next day. 
 
2.2.2 RNA extraction 
 
RNeasy Mini Kit (Qiagen) was used to extract the total RNA of INS-1 cells 
[76]. INS-1 cells seeded in 12-well plates after 24 h or 48 h were used. To 
begin with, cell pellets were obtained by trypsinization and centrifuge with 
cell number less than 1×106 in 1.5 ml Eppendorf tubes. Secondly, 350 μl 
RLT buffer (lysis buffer) was added into the pellet, followed by pipetting the 
mixture several times to obtain the homogeneous lysate; then, the same 
volume of 70% ethanol was added into the cell lysate and mixed gently. 
700 μl of cell lysate was transferred to a special RNeasy mini spin column, 
which was hold by a 2 ml tube. After centrifuged for 15 s at 8000 ×g, the 
flowthrough was discarded and the column was rinsed with 350 μl RW1 
buffer followed by centrifuge for 15 s at 8000 ×g again. In order to obtain 
purer RNA, the column was incubated with 20 units of RNase free-DNase 
(Qiagen) for 15 min and rinsed with 350 μl RW1 afterwards. Thirdly, the 
column was washed with 500 μl RPE buffer and centrifuged at 8000 ×g 
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twice for 15 s and 1 min, respectively. Thereafter, a new 1.5 ml Eppendorf 
tube replaced the container tube, and the RNA contained in the column 
filter was rinsed with 50 μl RNase-free water and centrifuged for 1 min at 
8000× g. Finally, the total RNA in the flowthrough was measured by Nano-
drop spectrophotometer and stored in -80˚C refrigerator if not intended for 
instant use. All the steps were performed on ice as far as possible, and the 
centrifuge was cooled down to 4˚C. 
 
2.2.3 cDNA preparation and SYBR green based real-time PCR 
 
cDNA from reverse transcription of mRNA was obtained by using reagents 
from Thermo Scientific. One reaction of the reverse transcription PCR (RT 
PCR) consisted of 4 μl 5× reaction Mix, 2 μl Maxima Enzyme Mix, RNA 
template (less than 5 μg) and topped up to 20 μl with DEPC water. After 
gentle mixing and centrifuge, the mixture was placed in a PCR machine 
(UNO Ⅱ, Biometra) and incubated at 25˚C for 10 min followed by 50˚C for 
15 min. Finally, the reaction was terminated by heating at 85˚C for 5 min. 
The concentration of cDNA was measured by a Nano-drop 
spectrophotometer. The cDNA product was stored at -80˚C refrigerator if 
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Table 2. The components for RT-PCR (one reaction) 
Reagents Volume 
5X reaction Mix 4 μl 
Maxima Enzyme Mix 2 μl 
Template RNA <5 μg 
Water, nuclease-free top up to 20 μl 
 
 
SYBR green based real-time PCR was utilized to assess the knockdown of 
HAP1 at mRNA level. Each sample was assayed in triplicate in the 96-well 
fast optical plate. One reaction mix contained 10 μl of 2× SYBR green 
master mix, 1 μl of 10 mM forward primer, 1 μl of 10 mM reverse primer, 
500 ng of cDNA template, and finally, topped up to 20 μl with DEPC water. 
The reagents were added carefully into the well to avoid bubble in the 
solution. Next, the 96-well plate was sealed tightly with MicroAmp optical 
adhesive film. After a brief centrifuge to remove the reaction mixture in the 
well wall, the plate was inserted into a real-time PCR machine (ABI 7500 
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Table 3. The components for SYBR green real-time PCR (one reaction) 
Reagents volume 
2× SYBR master mix 10 μl 
primer forward 1 μl (10 mM) 
primer reverse 1 μl (10 mM) 
cDNA template < 500 ng 
DEPC water top up to 20 μl 
 
Table 4. Parameters of performing SYBR green real-time PCR 
Steps Settings 
1 94˚C, 10 min 
2 94˚C, 5 s 
3 55˚C, 45 s 
4 72˚C, 1 min ; go back to step 2, 40 cycles 
5 72˚C, 10 min 
 
In negative control, water was used to substitute the cDNA template. And, 
the real-time PCR products were proceeded to run electrophoresis to 
confirm that non-specific amplification did not exist.  
 
The real-time PCR data were analyzed by the ABI 7500 Fast System SDS 
software. The relative gene expression levels of HAP1 were compared with 
β-actin, used as the internal control. 
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Table 5. Primers for SYBR green real-time PCR 
Gene name Amplicon Primer 
β-actin 168bp Forward  5’-GCTCTTTTCCAGCCTTCCTT-3’ 
Reverse   5’-CTTCTGCATCCTGTCAGCAA-3’ 
HAP1 isoform 
A 
111bp Forward  5’-TCCCCAATTCCTCTACCCTC-3’ 
Reverse   5’-AGCCTCTGAGAGTCCTGGGT-3’ 
HAP1 isoform 
B 
106bp Forward  5’-AGAAGGTGGTCCCGAAAGAC-3’ 
Reverse   5’-AGCCTCTGAGAGTCCTGGGT-3’ 
Note: the primers for β-actin were from a published paper [77]. And, the 
primers for HAP1 transcripts [rat HAP1 isoform A, NM_024133.2 and rat 






Transient transfection of StealthTM siRNA duplexes was conducted using 
LipofectamineTM 2000 (Invitrogen) [78]. The sequences of 3 siRNA oligos 
targeting rat HAP1 were shown in Table 6. The pooled siRNA oligo mixture 
was prepared as following: 36 μl of three siRNA oligos (20 nM) was added 
into 2 ml Opti-MEM medium; at the same time, 40 μl Lipofectamine 2000 
was mixed with 2 ml Opti-MEM medium. The two solutions were separately 
incubated for 5 min with occasional gentle mixing. Scrambled siRNA oligo 
with similar GC content as HAP1 siRNA oligo was used as negative 
control. Next, the two solutions were mixed together and incubated for 20 
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min to obtain the transfection complex. Meanwhile, INS-1 cell pellet was 
prepared by trypsinization and centrifuge, resuspended in INS-1 media 
without antibiotics and diluted to 1.6×106/ml for transfection use. 
Afterwards, the same volume of transfection mixture and INS-1 cells were 
added into multi-well plates and mixed gently. The transfection media were 
replaced by normal INS-1 culture media on next day.  The final 
concentration of components in the process was 90 nM siRNA, 5 μl/ml 
Lipofectamine 2000 and 0.8×106 cells /ml.  
 
SYBR green Real-time PCR and Western blotting were executed to 
determine the knockdown efficiency at the levels of mRNA and protein, 
respectively.  
 
Table 6. Sequences of siRNA duplex targeting rat HAP1 mRNA 
1 Anti-guide strand 5’CAUAGUGGGUGACAGAACCUGCAGG3’ 
Guide strand 5’CCUGCAGGUUCUGUCACCCACUAUG3’ 
2 Anti-guide strand 5’UGGAAGUGCAUCCAGAGGCACACUG3’ 
Guide strand 5’CAGUGUGCCUCUGGAUGCACUUCCA3’ 
3 Anti-guide strand 5’AUAUGUAGCGGGUCCAUGGUGCGUC3’ 
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2.2.5 Measurement of DNA content  
 
DNA quantity in cells is relative stable; thus, it is often used to normalize 
data in some experiments. The fluorescent dye Hoechst 33258 has specific 
binding affinity to the AT-rich regions of DNA. DNA quantity can be 
measured through its optic absorption at the excitation wavelength of 346 
nm and the emission  wavelength of 460 nm [79]. 
 
INS-1 cells treated with scramble or HAP1 siRNA were cultured in 24-well 
plates. After trypsinization and centrifuge, the cell pellets were 
resuspended with 1 ml PBS in 1.5 ml tubes. Next, aliquots of 200 μl cell 
suspension were disrupted on ice by a sonicatior (Sonics, Vibra Cell) under 
the condition of amplitude 40, output 3~5 watts, 5 s each for three times. At 
the same time, a set of standard DNA with serial dilution was prepared as 
12.5 μg/ml, 25 μg/ml, 50 μg/ml, and 100 μg/ml. Afterwards, 10 μl of the 
samples or standard DNA was added into the 96-well plate; each well was 
filled with 190 μl of 1 μg/ml Hoechst 33258 in 0.05 M Na2HPO4 and 2 M 
NaCl. After incubation at 37˚C for 30 min, the absorbance value was 
obtained by using a fluorescence microplate reader (Tecan M200). All the 
values were corrected by subtracting the blank. The DNA content of the 
samples was calculated according to the standard curve.  
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In this study, DNA content was used to represent the cell number. At the 
same time, the cell number was also counted to obtain the preliminary data 
about change in the cell number. INS-1 cells in 24-well plates were treated 
with scrambled or HAP1 siRNA for 48h or 72h. After trypsinization, the cell 
pellet in each well was resuspended in 1 ml culture media. Subsequently, 
the cells were counted by hemocytometer. 
  




INS-1 cells were cultured in 6-well plates for 2 or 3 days treated with 
scrambled or HAP1 siRNA oligos as previously mentioned in the 
knockdown method. The cells were trypsinized to obtain the cell pellet and, 
subsequently mixed with 200 μl lysis buffer (0.1mM PMSF, 150 mM NaCl, 
1mM EDTA, 50mM Tris-HCl, and 10 μg/ml each of pepstaitin, aprotinin, 
and leupeptin) by several moderate pipetting.  Next, the mixture was 
exposed to sonication, three times, 5 s each. Afterwards, the cell lysate 
was transferred to a 1.5 ml Eppendorf tube, and centrifuged with Eppendorf 
bench-top at 4˚C, 14,000 rpm for 10 min. The supernatant was aliquoted 
and reserved at -80˚C refrigerator for later protein concentration 
measurement or Western Blotting. 
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Measurement of protein concentration 
 
Bio-Rad protein assay kit based on Bradford method was used in 
quantitation of protein concentration [80]. The Bradford-type assay 
reagents, R-250 and G-250, are Coomassie dyes. When binding to 
primarily basic and aromatic amino acids, the R-250 (red-tinted) form 
changes to G-250 (green-tinted) form. The number of Coomassie dye 
ligands bound to each protein molecule is approximately proportional to the 
number of positive charges found on the protein. Protein-binding causes 
the dye to change from reddish-brown to bright blue and its maximum 
absorption is at 595 nm.   
 
To begin with, a series of diluted concentrations of standard protein of BSA 
(bovine serum albumin) were prepared as 1500 ng/μl, 750 ng/μl, 375 ng/μl 
and 187.5 ng/μl in order. 10 μl of standard protein or samples were added 
into 96-well plate separately in triplicate. Next, each well was top up to 200 
μl with 20% Bio-Rad Protein Assay Dye reagent. The protein lysis buffer 
replaced the protein samples to obtain the blank. After incubated at room 
temperature for 30 min, the plate was inserted into a microplate reader 
(Tecan M200) and the absorbance was measured at wavelength 595 nm. 
All the readings from the samples and standard protein were corrected by 
the blank. The sample protein concentration was calculated according to 
the dilution factors and standard curve in the same experiment.  
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Western Blotting 
 
The Western blotting is a widely used analytical method to identify specific 
proteins in the given sample of extract [81].  
 
Ten μg of total protein from INS-1 cell extract or rat brain extract (sc-2392, 
SantaCruz) was added into 1.5 ml tubes. After injecting with 4× DualColor 
Loading buffer and 20× reducing reagent Dtt, the tubes were put in a heat 
block at 95˚C for 5 min. The 10% SDS-polyacrylamide gel was prepared, 
which consisted of two parts: running part and stacking part. Next, the gel 
was submerged in the tank buffer (0.025 mM Tris, 0.1% SDS, 0.192 M 
glycine, pH 8.3). Thereafter, the samples and protein standard 
(kaleidoscope prestained standard molecular weight marker, Bio-Rad) were 
loaded on the slots of the gel and separated at the condition of 220V, 4mA, 
4W for 80~100 min (Power EPS 601,GE) to obtain distinct binds. 
Afterwards, the Polyvinylidine difluoride (PVDF) membrane (0.45 μm) was 
immersed in methanol for 5 min and then washed by semi-dry buffer (25 
mM Tris, 15% methanol and 250 mM glycine). Subsequently, the SDS-
polyacrylamide gel containing separated proteins was placed onto the 
PVDF membrane and tightly sandwiched by two wet cotton pads. The 
proteins in the gel were transferred onto the PVDF membrane at 23 V, 329 
mA, 5W for 30 min by a semi-dry transfer machine (Bio-Rad, Trans-Blot SD, 
semi-dry transfer cell). Upon successful transfer, the membrane was 
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blocked under gentle agitation in TBS-T buffer (20 mM Tris-HCl, 150 mM 
NaCl and 0.1% Tween-20, pH 7.5) containing 5% non-fat milk for 2 hours 
at room temperature. After that, the membrane was incubated with the 
primary antibody for 2 hours at room temperature or overnight at 4˚C under 
gentle agitation, following by rinse with TBS-T three times, 10 min each. 
Thereafter, the second antibody conjugated with horseradish peroxidase 
was used to incubate the membrane for 1 hour at room temperature, 
followed by rinse with TBS-T three times, 10 min each. Finally, the 
membrane was incubated in SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) for 2 min. And, the signals were detected by 
the photographic film. The film was scanned by a scanner (EPSON 1680) 
and the density of bands was analyzed by the analysis software 
(ImageMeter, version 1.11).  
 
Table 7. Some conditions in Western Blotting 
 Primary antibody Second antibody 
Catalogue NO. Dilution Catalogue NO. Dilution 
HAP1 SC-8769 1:500 SC-2350 1:2000 
GAPDH SC-335 1:2000 SC-2004 1:4000 
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 2.2.7 Assessment of insulin secretion  
 
Insulin sample collection 
 
Insulin stored in INS-1 cells will secrete into media upon the stimulation of 
glucose or other secretagogues. For this test, insulin, not only secreted in 
the extracellular media but also stored in the cellular insulin granules, was 
collected separately. The total insulin included in the granules was 
extracted by destroying the cell membranes with acid- ethanol. 
 
As mentioned above, INS-1 cells were cultured in 24-well plates in advance. 
To begin with, the 24-well plate was put into a water bath tank with its 
bottom submerged in the 37˚C water for 5 min; then, the media in each well 
were removed and the cells were washed with KRBH buffer. Next, the cells 
were incubated with 0.5 ml KRBH buffer containing 2.8 mM glucose for 30 
min. Afterwards, the media in each well were replaced by the solution 
containing different secretagogues such as 16.7 mM glucose or 1 μM 
forskolin, and incubated for 30 min again. Subsequently, 400 μl 
extracellular media with released insulin in each well was collected into 1.5 
ml Eppendorf tubes and centrifuged at 6,000 rpm for 6 min in an Eppendorf 
bench-top. The supernatants containing extracellular insulin was 50× 
diluted with RIA assay buffer and stored at -20˚C for the late RIA 
experiment. At the same time, all the cells left in the wells were exposed to 
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900 μl acid ethanol (70% ethanol, 0.5% hydrogen chloride) and sealed 
tightly with Parafilm for overnight. The solution containing the total cellular 
insulin in each well was collected in 1.5 ml tube and centrifuged at 6,000 
rpm for 6 min. Similarly, the supernatant was 1,600× diluted with RIA assay 
buffer and stored at -20˚C for later use. 
  
Radioimmunoassay (RIA) of rat insulin 
 
The Millipore rat insulin RIA kit was used for this experiment [82]. In 
principle, a constant concentration of the 125I-labeled insulin can bind to a 
constant concentration of the insulin antibody in a limited way. If unlabeled 
insulin, for example, the sample, is added into the antigen-antibody mixture, 
there is a competition between the labeled and unlabeled insulin for the 
limited binding sites on the antibody. Namely, the antibody-bound labeled 
insulin will decrease as the unlabeled insulin increases in the system. 
Therefore, the antibody-125I-bound insulin can be measured after separated 
from the unbound tracer. A standard curve with increasing insulin 
concentrations can be set up and the insulin in samples can be calculated 
when compared with the standard curve.   
 
Below are the procedures for RIA. First, 100 μl of 125I-labeled insulin was 
pipetted to every 12×75 mm glass tubes. Tube 1 and 2 were left for 
counting the total 125I-insulin and thus not subject to the procedures below. 
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Tube 3 and 4 were added with 200 μl of RIA assay buffer; likely, tube 5 and 
6 with 100 μl. From tube 7 to 20, 100 μl of insulin standard with 0.1 ng/ml, 
0.2 ng/ml, 0.5 ng/ml, 1 ng/ml, 2 ng/ml, 5 ng/ml, and 10 ng/ml was added in 
duplicate. Two quality control solutions were added into tube 21 to 24 in 
duplicate. Next, 100 μl of samples was added into other tubes in sequence 
in duplicate. Afterwards, 100 μl of rat insulin antibody was added into the 
tubes except tube 1 to 4. After moderate vortex, all the tubes were covered 
with aluminum foil and incubated at 4˚C for overnight. On the second day, 1 
ml of precipitating reagent was injected into all the tubes . All the tubes 
were vortexed and incubated at 4˚C for 20 min; later, the tubes were 
centrifuged at 4˚C, 2400× g for 20 min. Immediately, all the supernatants 
were discarded by decanting, and the residual liquid was absorbed from 
the lip of tubes to towel papers. Finally, all the tubes were counted in a 
gamma counter (Wallac Wizard), which reported the insulin concentrations 
in every sample using a pre-set program comparing standard curve.   
 
2.2.8 Assessment of glucose metabolism by MTS test 
 
Glucose metabolism in β cells plays a vital role in stimulation of insulin 
secretion. A tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) can be 
bio-reduced into a soluble colored formazan product by NADH- and 
NADPH-dependent dehydrogenase in the metabolically viable cells. Thus 
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the amounts of formazan formed reflect the metabolic activity of living cells 
by measuring the absorbance at 490 nm [83].  
 
INS-1 cells were cultured in 24-well plates as previously mentioned in the 
knockdown experiments. After wash and pre-incubation with KRBH buffer 
for 30 min at 37˚C, INS-1 cells were incubated with 500 μl of KRBH buffer 
containing different concentrations of glucose and 100 μl MTS/PMS 
mixture (46 μg/ml PMS and 2 mg/ml MTS in DPBS) at 37˚C for 60 min. The 
blank well was treated in the same way except that there was no cell in it. 
Finally, the plate was measured in a microplate reader (Tecan 200) at the 
absorbance of 490 nm. All the data were subtracted with the blank and 
corrected with the cell number variation. 
 
2.2.9 Measurement of membrane potential 
 
The change in membrane potential of β cells is a key event in the process 
of insulin secretion and is important to understand the insulin exocytosis 
[84]. Membrane potential can be measured by a fluorescent probe bioxonol, 
a voltage-sensitive dye, at the excitation wavelength of 540 nm and the 
emission wavelength of 580 nm [85].  
 
INS-1 cells transfected with scrambled or HAP1 siRNA were cultured in 6-
well plates for 72 h. After trypsinization and centrifuge, cell pellets were 
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resuspended in culture media and incubated in 37˚C, 5% CO2 for 30 min 
for recovery. Subsequently, the cells were rinsed with KRBH twice and 
resuspended in a cuvette with 2 ml of pre-warmed KRBH. Biosoxonol was 
added into the cuvette at a final concentration of 100 nM and mixed 
completely with stirring. Cells in the cuvette with magnetic stirring bar in the 
bottom were incubated at 37˚C for about 15 min to reach a stable baseline. 
Afterwards, glucose and other nutrients were added into the cuvette to 
challenge the cells. All the readings of bioxonol fluorescence at the 
excitation wavelength of 540 nm and the emission wavelength of 580 nm 
were recorded by a spectrofluorometer (Perkin-Elmer LS-50B). The results 
were expressed as the percentage of approximately maximal 
depolarization status, which was obtained in the presence of 40 mM KCl in 
individual assays. 
 
2.2.10 Measurement of intracellular Ca2+ concentration  
 
The increase of intracellular free Ca2+ concentrations is essential to insulin 
secretion and it can trigger the exocytosis of insulin-containing granules. 
Fura-2 is a ratiometric and sensitive fluorescent probe for measuring 
intracellular Ca2+ concentration [86]. Fura-2/AM, a lipid soluble form of 
Fura-2, is a nonpolar compound and is permeable to cell membranes. 
Upon entering the cell, the Fura-2/AM is hydrolyzed into Fura-2 by 
intracellular esterases and becomes a polar molecular that is trapped 
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inside the cell. Fura-2 binds Ca2+ with 1:1 stoichiometry. The feature of 
ratiometric changes in fura-2 fluorescence of 510 emission wavelength at 
dual 340/380 nm excitation wavelengths allows this Ca2+ indicator to 
precisely measure the intracellular Ca2+ concentrations. Furthermore, this 
technique noticeably reduces the effects of unequal dye loading, dye 
leakage, as well as problems associated with measuring Ca2+ in the case 
of variation of cell number [87].  
 
INS-1 cells treated with scramble or HAP1 siRNA were cultured in 6-well 
plates for 72 h. After trypsinization and centrifuge, the cell pellets were 
resuspended and loading with KRBH containing 2 μM Fura-2/AM at 37˚C 
for 30 min. Afterwards, the cells were washed twice to discard extracellular 
indicator and then incubated in KRBH containing glucose or other nutrients 
for 30 min. Subsequently, the fluorescence ratio of 510 nm emission 
wavelength at alternative 340/380 nm excitation wavelengths was recorded 
by a fluorescence plate reader (Tecan M200). The final data were 
processed by subtracting the background value. Each assay was 
performed in triplicate.  
 
2.2.11 Investigation of cell growth and death 
 
Propidium iodide (PI) staining and flow cytometry can be used to analyze 
cell cycle, which may show some information on cell grow and death in the 
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mitosis [88].  INS-1 cells were cultured in 12-well plates as described 
previously. After trypsinization and centrifuge, cell pellets were 
resuspended in 0.5 ml PBS, followed by adding 4.5 ml 70% ethanol to fix 
for 2 h. After washed by PBS, the pellets were incubated in PI staining 
solution (1x PBS containing 0.1% triton X-100, 0.2 mg/ml RNase A, and 20 
μg/ml PI) for 30 min at room temperature. After that, the cells were 
subjected to a flow cytometer (CyAn ADP, Beckman Coulter) to analyze 
the cell cycle. Data were collected on a linear scale at the excitation of 488 
nm and the emission of 610 nm. The count events were set to ten thousand 
and the flow rate was set to about 150 events/s. Finally, the results of cell 
distribution at different phases of cell cycle were analyzed by the 
corresponding software, Summit 4.3. 
 
2.2.12 Caspase-3 activity assay 
 
Caspases are a family of proteases that mediate and execute apoptotic cell 
death, or programmed cell death [89]. Among them, caspase 3 is one of 
the executive enzymes of apoptosis [90]. Activation of caspase 3 can be 
assessed by a fluorimetric assay which is based on the fact that hydrolysis 
of a specific substrate [acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin 
(Ac-DEVD-AMC)] by caspase 3 results in the release of fluorescent 7-
amino-4-methylcoumarin (AMC). The AMC fluorescence can be measured 
at the excitation wavelength of 360 nm and the emission wavelength of 460 
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nm, respectively. The concentration of the AMC can be calculated by 
comparison to a standard curve obtained from known AMC solution.  
 
INS-1 cells cultured in 24-well plates were transfected with scramble or 
HAP1 siRNA for 48h and 72h. After one wash with cold PBS, 50 μl lysis 
buffer (0.1 mM PMSF, 150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCl, pH 7.2, 
and 10 μg/ml each of pepstaitin, aprotinin, and leupeptin) was added into 
each well. Cell lysate was collected by scraping with cell lifters and was 
sonicated for three times, 5 s each. The cell lysate was centrifuged at 
14,000 rpm, 4˚C for 10 min (Eppendorf bench-top) and the supernatant 
was aliquoted for protein quantitation or caspase activity measurement. 
 
A series of 200 μl diluted AMC solution in the concentration ranges of 100 
nM, 500 nM, 1 μM, 2 μM, 4 μM and 6 μM was added into a 96-well plate to 
establish the standard curve. 200 μl caspase-3 assay buffer (20 mM 
HEPES, pH 7.4, with 2 mM EDTA, 0.1% CHAPS, and 5 mM DTT) without 
AMC was used for blank wells. The samples containing 20 μg of protein 
were mixed with 200 μl reaction buffer (16.7 μM Ac-DEVD-AMC in 
caspase-3 assay buffer) in triplicate. After gentle swirling, the 96-well plate 
was subjected to a fluorescent reader (Tecan M200) in a kinetic mode 
every 10 min for 60 min at room temperature at the excitation of 360 nm 
and the emission of 460 nm, respectively. All the readings were corrected 
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by the value in the blank wells. The caspase-3 activity in the sample was 
calculated in comparison with the standard curve.  
 
2.2.13 Statistical analysis 
 
The results were expressed as mean ± SEM and analyzed by two tail t-test 
or one-way ANOVA. p < 0.05 was regarded as statistically significant. 
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3. RESULTS 
 
3.1 The role of HAP1 in insulin secretion 
 
3.1.1 Transfection of siRNA knocks down HAP1 in INS-1 cells 
 
The small RNA interference technique [RNAi] now has become one of the 
most powerful tools to analyze gene function due to its extraordinary 
specificity and efficiency. The siRNA-based approach is fast, easy and 
effective. And, higher levels of transfection efficiency can be obtained. 
Furthermore, our lab has successfully confirmed that INS-1 cells could be 
easily transfected with siRNA oligos [75]. StealthTM RNAi oligos from 
Invitrogen were used for this project because of decreased off-target 
effects, reduced nonspecific toxic stress responses, and slower 
degradation compared to standard siRNA. On the other hand, the 
transfection efficiency is affected by transfection reagents, siRNA amount 
and cell density [91, 92]. Based on the protocol of Invitrogen and previous 
experience in our lab, different dosages of HAP1 siRNA oligos or 
Lipofectamine 2000, cell density and various transfection periods (24-72h) 
were tested to optimize the knockdown efficacy. The equal amounts of 
scrambled siRNA oligo with similar GC percentage were used as the 
negative control.  
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The knockdown of HAP1 at mRNA level was verified by SYBR based real-
time RT-PCR. At each time point, total mRNA was extracted and converted 
into cDNA. As shown in Figure 2 A and B, the knockdown efficacy with 3 
HAP1 siRNA in combination was 75.3% for isoform A and 79.7% for 
isoform B at 24h after transfection; similarly, the knockdown efficacy at 48h 
was 72.2% and 74.0%, respectively. At both time points, the knockdown 
efficacy was more than 70% for both isoforms, indicating a recognized 
knockdown. At protein level, Western Blotting revealed marked knockdown 
of HAP1 at 48h and 72h after HAP1 transfection (Figure 2C). The HAP1 
antibody was from Santa Cluz biotechnology, which did not provide the 
HAP1 antibody showing separate isoform bands.  By optical densitometry, 
the density on knockdown bands decreased to 15.0% of control at 48h and 
17.3% at 72h (Figure 2D). These results indicated that the knockdown 
method by siRNA was effective for HAP1 in INS-cells. Thus, all the 
experiments on the functional assessments of HAP1 knockdown INS-1 
cells were carried out under these knockdown conditions. 
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Figure 2. Knockdown of HAP1 in INS-1 cells 
Knockdown of HAP1 in INS-1 cells was carried out by reverse transfection 
of three HAP1 siRNA duplex in combination. (A) and (B) show the 
knockdown results at mRNA level after 24h and 48h transfection as 
assessed by SYBR based real-time RT-PCR. The expression of both HAP1 
isoforms in INS-1 cells was decreased more than 70% compared to control, 
in which, the same concentration of scrambled siRNA was transfected.  (C) 
reveals marked knockdown of HAP1 at protein level by targeting siRNA as 
assessed by Western Blotting at two time points of 48h and 72h. 
Transfection of scrambled siRNA did not alter HAP1 mass in comparison 
with untreated INS-1 cells. Rat brain extract was utilized as positive control. 
(D) indicated that HAP1 protein mass was reduced to less than 20% of 
control at 48h and 72h. Values in (A), (B) and (D) are mean ± SEM from at 
least 3 independent experiments; ** p<0.01 vs. control. 
 
3.1.2 HAP1 knockdown inhibits stimulated Insulin secretion 
 
The insulin secretion result is one of the most important data in this project. 
As shown in Figure 1 in the Chapter 1, insulin secretion process is very 
complicated and regulated by several signaling pathways. Insulin content 
refers to the total insulin contained in the different compartments of β cells. 
The intracellular and extracellular insulin changes can imply the underlying 
variation in insulin secretion pathway [20]. The insulin secretion profile in 
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the INS-1 cells was examined by stimulating them with glucose or other 
secretagogues after HAP1 knockdown. If the stimulated insulin secretion 
was affected, some experiments was performed to investigate which 
important signaling events for insulin secretion might be involved in the 
alteration to explain the results.  
 
Figure 3A shows the insulin secretion by glucose stimulation at 48h after 
knockdown of HAP1. At the basal glucose concentration (2.8 mM), insulin 
secretion in the control or the siRNA groups was nearly at the same level 
(0.90% and 0.81% of total content, respectively). Upon the stimulation of 
physiological range glucose concentrations, 11.2 mM and 16.7 mM, insulin 
release in the control group was increased to 2.0 folds (1.83% of content) 
and 2.7 folds (2.41%) compared with the basal insulin secretion. However, 
glucose-stimulated insulin release was significantly inhibited in the HAP1 
knockdown group; insulin release was reduced by 30 % (1.45% of content) 
at 11.2 mM and by 33% (1.81% of content) at 16.7 mM (both p<0.05 vs. 
controls). In addition, at the joint stimulation of 16.7 mM glucose and 1 μM 
forskolin, an insulin secretion potentiator, insulin secretion in the control 
group was increased by 5 to 6 folds over the basal secretion which, 
however was affected after HAP1 knockdown.  
 
The data of glucose-stimulated insulin secretion at 72h HAP1 knockdown 
are similar to those observed at 48h (Figure 3B). The insulin secretion was 
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significantly reduced by 56% (1.37% of content) at stimulation of 11.2 mM 
glucose and decreased by 76% (1.95% of content) upon 16.7 mM glucose 
in the HAP1 knockdown group compared to the control group (both 
p<0.05). Also alike that at 48h, insulin secretion stimulated by the 
combination of 16.7 mM glucose plus forskolin was not significantly altered 
by 72h HAP1 knockdown. 
 
In addition, insulin secretion stimulated by other secretagogues was also 
examined after 72h HAP1 knockdown (Figure 3C). In the presence of 0.1 
mM tolbutamide, an insulin potentiator by closing ATP-sensitive K+ 
channels, insulin secretion at both 5.6 mM and 16.7 mM glucose was 
decreased in HAP1 knockdown cells. For the latter; the insulin secretion 
was increased from 0.92% to 2.87% in the control, and from 1.01% to 
1.94% in the HAP1 knockdown, indicating a reduction by 52% (p<0.01) in 
HAP1 knockdown cells. Upon the stimulation of 40 mM KCl, the increase of 
insulin secretion was also significantly inhibited by 65% from 130% in the 
control to 45% of basal (p<0.05) in knockdown cells. On the other hand, the 
5-6 fold insulin secretion upon the joint stimulation of 10 mM glucose and 
0.1 mM IBMX, a potentiator of insulin secretion, was not affected by 
knockdown of HAP1. 
 
The total insulin content in INS-1 cells was extracted by acid ethanol and 
their DNA content was also determined as the indicator of cell number. The 
	   51	  
insulin content was expressed as the ratio of total insulin and DNA content. 
As shown in Figure 3D, HAP1 knockdown at 72h did not change the insulin 










Figure 3. Effects of HAP1 knockdown in INS-1 cell on insulin secretion 
induced by glucose and other secretagogues  
 
INS-1 cells in 24-well plates were treated with scrambled or HAP1 siRNA 
oligos for 48h or 72h. The cells were rinsed and pre-incubated in basal 2.8 
mM glucose for 30 min. Afterwards, the cells were stimulated with different 
concentrations of glucose or other secretagogues for another 30 min. The 
supernatants containing released insulin in each well was collected and the 
total cellular insulin was extracted by acid-ethanol for measurement by RIA. 
The insulin secretion was expressed as percentage of insulin content in 
each well. (A) and (B) show the results after HAP1 knockdown of 48h and 
72h, respectively. (C) shows the secretion results stimulated by some 
secretagogues (G: glucose; TOL: 0.1 mM tolbutamide; IBMX, 0.1 mM; KCl, 
40 mM). (D) shows the insulin content after 72h HAP1 knockdown in each 
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well, which was normalized by DNA content. Values are mean ± SEM of 3 
independent experiments. * p< 0.05 and ** p< 0.01 vs. control 
 
 
3.1.3 Knockdown of HAP1 does not affect glucose metabolism  
 
Glucose metabolism in β-cells, indicated by ATP/ADP ratio change, plays a 
vital role in insulin secretion pathway. Formazan, a bioreduced product of 
the tetrazolium MTS by NADH- and NADPH-dependent dehydrogenases, 
can be directly measured at the absorbance of 490 nm. Thus, to some 
extent, formazan could reflect the glucose metabolism in the INS-1 cells. 
As shown in Figure 4, the formazan product was increased with the 
increase of glucose concentrations both in the scrambled and knockdown 
groups. In HAP1 siRNA transfected cells, the formazan production was 
similar to the control cells at 4 conditions: 0 mM, 2.8 mM, 16.7 mM glucose, 
and 16.7 mM glucose plus 1 μM forskolin (all p>0.05). Therefore, it 
appeared that HAP1 knockdown in INS-1 cells did not induce changes in 
glucose metabolism. 
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Figure 4. HAP1 knockdown did not change glucose metabolism 
 
INS-1 cells in 24-well plates were treated with scrambled or HAP1 siRNA 
for 72h. After one wash with KRBH buffer, the cells were incubated with 
MTS reagents at different glucose concentrations (from 0 to 16.7 mM) and 
1 μM forskolin for 1 h.  The absorbance of colored formazan at each 
condition was measured at 490 nm and subtracted by the blank. The 
values are expressed as mean ± SEM of 4 independent experiments.  
 
 
3.1.4 Knockdown of HAP1 does not alter membrane potential 
 
Depolarization of membrane potential plays a key role in the coupling of 
metabolic signals to opening of Ca2+ channels in glucose-stimulated insulin 
secretion from β-cells. This process is mediated by the increase of 
ATP/ADP ratio, which leads to the closure of ATP-sensitive K+ channels 
and subsequent depolarization resulting in Ca2+ channel opening.  At the 
basal glucose concentration, the resting membrane potential in HAP1 
knockdown cells exhibited a similar status (80.0 ± 3.12% vs. 79.8 ± 2.52% 
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of maximal depolarization in control cells, p>0.05, Figure 5A,B). 
Subsequently, the stimulation of 16.7 mM glucose led to depolarization of 
membrane potential to the similar level in both control and HAP1 
knockdown cells (89.3 ± 2.35% vs. 87.8 ± 1.85% in control, p>0.05, Figure 
5A,B). In addition, the incremental depolarization after 16.7 mM glucose 
stimulation did not reveal a significant change (11.6 ± 2.81% vs. 10.2 ± 
3.03% in control, p>0.05, Figure 5C). Furthermore, 100 μM diazoxide, an 
activator of KATP channels, could reverse the glucose-induced membrane 
potential depolarization to the basal level (80.6 ± 2.85% vs. 81.2 ± 1.90% in 
control, p>0.05, Figure 5A,B). Thus, HAP1 knockdown did not affect the 
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Figure 5. HAP1 knockdown at 72h did not alter membrane potential in INS-
1 cells. 
  
The membrane potential of INS-1 cells at resting or after stimulation was 
showed as percentage of maximal membrane potential depolarization, 
which was obtained at a saturating concentration of KCl (40 mM). (A,B) 
The membrane potential in control and HAP1-siRNA knockdown cells 
showed similar changes at the basal (2.8 mM glucose), after 16.7 mM 
glucose stimulation, and after hyperpolarization by adding 100 μM 
diazoxide (DIZ). (C) After 16.7 mM glucose stimulation, the increase of 
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membrane depolarization also did not show significant changes between 
the two groups. Values are mean ± SEM of 3 independent experiments.  
 
 
3.1.5 Knockdown of HAP1 does not change [Ca2+]i  
 
The increase of intracellular Ca2+ upon stimulation triggers the exocytosis 
of insulin secretion in β-cells, and the possible effect of HAP1 on [Ca2+]i 
was also examined. The ratio of fluorescence of Fura-2 at 340/380 nm 
excitation wavelengths represents the intracellular Ca2+ concentration. As 
shown in Figure 6A, the basal [Ca2+]i in both the control and HAP1 
knockdown cells was nearly at the same level. After 16.7 mM glucose 
stimulation, the ratio increased to 1.31 ± 0.16 and 1.30 ± 0.17 in the control 
and knockdown cells, respectively. However, there was no significant 
difference in glucose-induced [Ca2+]i rises between the 2 groups of cells 
(p>0.05). In addition, the [Ca2+]i rises induced by both high KCl and 
ionomycin were also not reduced by HAP1 knockdown. For the former, 34 
mM KCl increased similar fluorescence ratio between the control and 
knockdown cells (1.46 ± 0.04 vs. 1.47 ±0.06, p>0.05) (Figure 6B). For the 
latter, such ratio was even a bit higher in the knockdown cells (3.32 ± 0.61 
vs. 2.66 ± 0.27 of control, p<0.05) upon the stimulation of 2 µM ionomycin 
(Figure 6C). Taken together, HAP1 knockdown did not affect the 
intracellular Ca2+ concentration in INS-1 cells upon the stimulation of high 
concentration glucose and KCl. 
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Figure 6. HAP1 knockdown did not affect intracellular free Ca2+ 
concentration. 
 
INS-1 cells in 24-well plates were treated with scrambled or HAP1 siRNA 
oligos for 72h. Upon the harvest of cell pellets, the cells were recovered 
and loaded with Fura-2. After washing, cells were incubation with 2.8 mM 
glucose for 30 min. The ratio of fluorescence at 510 nm emission was 
measured at 340/380 nm excitation, which reflects the Ca2+ concentration. 
(A), (B) and (C) show the changes of [Ca2+]i after the stimulations of 16.7 
mM glucose, 34 mM KCl and 2 µM ionomycin. Values were mean ± SEM 
from 3 independent experiments.  
 
3.2  The role of HAP1 in cell cycle 
 
3.2.1 Knockdown of HAP1 affects INS-1 cell growth 
 
There is evidence that HAP1 may be involved in intracellular trafficking and 
cell cycle [51]. Thus, the effect of HAP1 in INS-1 cells was examined after 
reverse transfection targeting HAP1 at 48h and 72h. After HAP1 
knockdown, there was a significant change in the cell number between the 
control and HAP1 knockdown group. According to my observation under 
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microscope, the confluence of knockdown group was not as high as that of 
control group at 24-well plate after 48h or 72h. In addition, the INS-1 cells 
of HAP1 knockdown displayed a slightly rounded-up pattern and their 
pseudopods were not stretched as far as seen in the control cells. When 
the number of cells in per well was counted, a significant reduction was 
observed after HAP1 knockdown. For example, at 72h, the cell number in 
the control and siRNA treated cells was 0.33±0.01×106 and 
0.29±0.02×106/well a 13% reduction in the knockdown cells (p<0.05). The 
effect of HAP1 knockdown on cell number was confirmed by 
measurements of the DNA content per well. At 48h (Figure 7A), the DNA 
concentration in the control and siRNA-treated cells was 119.6 μg/ml and 
104.8 μg/ml (p<0.05), corresponding to a 12.3% reduction. Similarly, the 
DNA concentration at 72h (Figure 7B) was 127.4 μg/ml in control and 110.3 
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Figure 7. HAP1 Knockdown decreased INS-1 cell growth. 
INS-1 cells were transfected with scrambled or HAP1 siRNA oligos for 48h 
(A) and 72h (B). After trypsinization, the cell pellet in each well was diluted 
with PBS, and the same volume solution in control and knockdown cells 
was sonicated to release DNA, which was calculated according to a 
standard DNA curve. Values are mean ± SEM of 3 independent 
experiments. * p<0.05 vs. control. 
 
3.2.2 Knockdown of HAP1 causes changes in the cell cycle 
 
One study has reported that HAP1 was highly expressed throughout the 
cell cycle by Immunofluorescence confocal microscopy in mice [51]. Thus, 
HAP1 may take part in the mitosis of INS-1 cells. The potential effects of 
HAP1 knockdown on INS-1 cell growth and death were further investigated 
by PI staining followed by flow cytometry. At 48h (Figure 7A), there was no 
significant difference for the number of cells at the sub-G1 phase (7.2 ± 
0.51% vs. 6.5 ± 0.83% in control, p>0.05); suggesting no clear subdiploidy 
apoptosis. However, HAP1 knockdown decreased cells at G1/G0 phase 
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(73.1 ± 1.26% vs. 77.1 ± 2.48% in control, p<0.05), and increased cells in S 
phase (7.0 ± 0.58% vs. 5.1 ± 0.89% in control, p<0.05) and G2/M phrase 
(14.4 ± 0.71% vs. 11.5 ± 0.81% in control, p<0.05). Similarly, at 72h (Figure 
7B), HAP1 knockdown reduced cells in G1/G0 phase (83.7 ± 1.57% vs. 
80.0 ± 0.67% in control, p<0.05) and increased cells in G2/M phase (12.4 ± 
0.69% vs. 9.3 ± 0.79% in control, p<0.05). In addition, a minor increase of 
cells in the S phase was observed at 48h but not at 72h. Thus the 
percentages of cells at sub-G1 (under subdiploidy apoptosis) due to DNA 
fragmentation at 48h and 72h after HAP1 knockdown were not changed. At 
the two time points, the cells at G1/G0 phase were reduced whereas more 
cell were accumulated in the S and G2/M phases after HAP1 knockdown. 
These results suggest that HAP1 is implicated in the regulation of cell cycle 
in INS-1 cells. 
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Figure 8. HAP1 knockdown did not induce apoptosis but changed cell cycle 
in INS-1 cells. 
 
INS-1 cells in 24-well plate were treated with scrambled or HAP1 siRNA for 
48h (A) and 72h (B), followed by PI staining and flow cytometry analysis. 
INS-1 cells were sorted into sub-G1, G1/G0, S and G2/M phases. Values 
are mean ± SEM from 3 independent experiments. * p<0.05 
 
 
3.2.3 Knockdown of HAP1 does not activate caspase-3 
 
 
Caspase-3 is involved the later stage of apoptosis and its activation is 
considered as a solid indicator of apoptotic cell death. In this 
study,caspase-3 activity was measured by the hydrolysis of its specific 
substrate, Ac-DEVD-AMC, which releases the cleaved fluorescent AMC. 
As shown in Figure 9A, at 48h HAR1 knockdown, the AMC values were 
161.5 nM in the control and 162.7 nM in HAP1 knockdown cells, 
respectively (p>0.05). Similarly, caspase-3 activity was not increased after 
HAP1 knockdown for 72h (Figure 9B); the AMC values were 157.7 nM in 
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the control and 159.3 nM in HAP1 knockdown cells, respectively (p>0.05). 
Thus knockdown of HAP1 in INS-1 cells appeared not to activate caspase-




 Figure 9. HAP1 knockdown in INS-1 cell did not activate caspase 3. 
INS-1 cells in 24-well plates were treated with scrambled or HAP1 siRNA 
duplexes for 48h (A) or 72h (B). Afterwards, proteins were extracted and 
the same amount of protein, 20 μg, was used in the caspase 3 assay. The 
caspase 3 activity in the HAP1 knockdown INS-1 cells did not show 
significant changes at both time points. The fluorescence from AMC 
represents caspase 3 activity. All the results are mean ± SEM from 3 
independent experiments. 








The goal of this study is to investigate the potential role of HAP1 in insulin 
secreting cells. In my project, I utilized the RNAi (RNA interference) 
technique to knock down HAP1 and then examine the functional changes 
in a pancreatic β-cell model, INS-1 cell.  
 
Small interfering RNA is a group of double-stranded RNA molecules, which 
participate in numerous biological processes in cells [78]. siRNA is involved 
in the RNAi pathway, which interferes with the expression of specific 
genes. Synthetic siRNA duplexes can be artificially introduced into cells by 
several transfection methods. One strand of siRNA combines with proteins 
to form RISC (RNA induced silencing complex) and cleaves the target site 
of mRNA, thus silencing the specific gene by complementarity. By silencing 
a specific mRNA, the function of its relevant protein can be examined. 
Nowadays, siRNA has become a popular and mature technique in 
biomedical research. However, there are still some disadvantages in this 
method. First, too much siRNA introduced into cells may be recognized as 
virus by-products and trigger cell inflammation events as a result of the 
activation of innate immune responses. Second, genes, partly matched 
with target gene, may be down-regulated by the siRNA to some extent, 
which may lead to nonspecific effects causing problems in result analysis 
and data explanation. Finally, the process of siRNA transfection into cells 
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inevitably involves the transient opening of pores or “holes” in the cell 
membrane, which can induce morphological abnormalities in target cells.  
 
To avoid the limitations of this method, I took some measures to optimize 
the knockdown process. First, on the premise of ensuring the effective 
knockdown, I tried the transfection at different concentrations of HAP1 
siRNA oligos and ultimately took the relatively low siRNA concentration to 
obtain the satisfactory result. Subsequently, I used 3 different siRNA 
targeting HAP1 in combination to reduce the amount of individual siRNA 
oligo in order to prevent that too much of a single siRNA could trigger the 
off-target effects and cell inflammation reaction. Second, the same amount 
of scramble siRNA oligos with similar content of GC was transfected into 
control cells, which would validate the changes observed in the cells with 
target siRNA to HAP1. At the concentration used in my study, scramble 
siRNA oligos had no apparent effects on the cell functions I examined 
when comparing to the non-transfected cells. In despite of many 
transfection methods available, such as electroporation and virus, I took 
one of the most effective and mature methods, i.e. the liposome-based 
transfectant Lipofectamine2000, a cationic polymers. Lipofectamine2000 
can form a similar contracture as cell membrane and actually fuse with cell 
membrane, followed by discharging the target siRNA into cells. Our lab has 
used this protocol previously to transfect other siRNA oligos in INS-1 cells 
to knock down interest proteins successfully [75]. At 24h of transfection, I 
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observed that INS-1 cells were not tightly adhesive to the bottom of 
vessels. Thus, some functional assessments requiring multiple washing 
and incubation were executed at 48h and 72h after siRNA transfection. The 
effective knockdown of HAP1 was achieved at both the mRNA and protein 
level during these periods. 
 
4.1 Roles of HAP1 in insulin secretion pathway 
 
Insulin secretion from INS-1 cells after HAP1 knockdown was effected. 
Upon the stimulation of high concentrations of glucose in physiological 
range, insulin secretion was decreased over the control. In addition, at the 
condition of high glucose with tolbutamide, and 40 mM KCl, the stimulated 
insulin secretion was also reduced.   
 
There is evidence for that HAP1 is associated with intracellular vesicle 
trafficking in cells of nervous system [57]. On the other hand, the process 
of insulin secretion links with intracellular trafficking and involve many 
signaling pathways for its regulation. Thus the inhibition of insulin secretion 
by HAP1 knockdown could result from a reduction of insulin content by 
affecting biosynthesis, the interference with of insulin secretion process, or 
in combination. However, it appears that HAP1 may not play an important 
role in insulin biosynthesis, since knockdown of HAP1 did not alter the 
insulin content in INS-1 cells. Thus the inhibition of stimulated insulin 
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secretion after HAP1 knockdown could be due to the adverse effects on the 
signal transduction implicated in the regulation of insulin secretion. Insulin 
secretion pathway is very complex and regulated by a network of signals 
(c.f. Figure 1). The glucose stimulated insulin secretion was significantly 
affected by HAP1 knockdown, and the underlying mechanisms were 
investigated by performing the experiments to examine the critical signaling 
events in this process.  
 
To this end, three sets of experiments were carried out to dissect the key 
events in insulin secretion pathway, i.e. glucose metabolism, membrane 
potential and intracellular Ca2+ concentration. First, general glucose 
metabolism was assessed by detection of the reduction of a tetrazolium 
salt through NAD(P)H production from glycolysis and mitochondrial 
phosphorylation. It is known that glucose must be metabolized to generate 
metabolic coupling factors to stimulate insulin secretion in β-cells, among 
which is an increase in the ATP/ADP ratio. However, HAP1 knockdown did 
not affect glucose metabolism. In the second set of experiments, glucose-
induced membrane potential was examined. An increase of ATP/ADP ratio 
can cause the closure of KATP channels leading to membrane potential 
depolarization in β-cells, which is followed by the opening of voltage-
operated Ca2+ channels. When HAP1 in INS-1 cells was knocked down, 
however, the glucose-induced membrane depolarization was not 
significantly affected, suggesting that HAP1 might not be implicated in this 
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signaling event. This notion is further supported by the fact that although 
tolbutamide, which bypasses glucose metabolism to depolarize membrane 
potential by directly closing KATP channels, could still depolarize INS-1 cells 
after HAP1 knockdown similarly to the control cells, it was unable to 
recover the inhibition of glucose-stimulated insulin secretion in these cells. 
These results indicate that HAP1 knockdown interfere with glucose-
stimulated insulin secretion beyond the steps of membrane depolarization. 
Finally, the intracellular Ca2+ concentrations ([Ca2+]i) in INS-1 cells were 
determined; it is well recognized that a rise of [Ca2+]i can trigger exocytosis 
to secrete insulin from β-cells. Surprisingly, HAP1 knockdown did not 
reduce glucose-induced [Ca2+]i rise in INS-1 cells. Furthermore, [Ca2+]i 
elevations by high KCl which depolarizes membrane potential and 
activates Ca2+ channels or by the Ca2+ ionophore ionomycin also not 
affected by HAP1 knockdown. These results together indicate that HAP1 
does not play an important role in the regulation of [Ca2+]i.   
 
To define the underlying mechanism for the inhibition of glucose-stimulated 
insulin secretion after HAP1 knockdown, I also examined the insulin 
release induced by other secretagogues. Although [Ca2+]i elevations by 
high KCl was not affected, insulin secretion upon this stimulation was 
significantly inhibited. This suggests that a step after [Ca2+]i rise in the 
insulin secretion involves HAP1. IBMX and forskolin are strong potentiators 
of glucose-stimulated insulin secretion. The former is a phosphodiesterase 
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inhibitor and the latter activates adenylyl cyclase, leading to elevation of 
cAMP level and activation of PKA. Both IBMX and forskolin can promote 
the glucose-induced insulin secretion by two fold. Interestingly, there was 
no significant change in glucose-stimulated insulin secretion in the 
presence of IBMX or forskolin after HAP1 knockdown in INS-1cells.  All 
these observations indicate that HAP1 knockdown interfered with glucose-
stimulated insulin secretion beyond [Ca2+]i rise and such inhibition could be 
reversed by cAMP elevation and PKA activation. Thus, HAP1 may be 
involved in the intracellular vesicles trafficking and exocytosis, such as the 
mobilization of insulin-containing granules from reserved pool to docked 
pool in order to meet the need of rapid release. There is evidence that 
HAP1 is involved in the intracellular vesicles trafficking in nervous cells, as I 
mentioned in the Introduction chapter. Recently Cape et al. found that 
glucose-mediated insulin release was decreased in conditional HAP1 
knockout mice by Cre-loxP system [93]. Under electron microscope, there 
was a reduced number of insulin-containing vesicles docked at the plasma 
membrane of islets in these mice. However, the exact mechanism for the 
action of HAP1 in this scenario remains to be elucidated.  
 
My finding of inhibition of glucose-stimulated insulin secretion in INS-1 cells 
after HAP1 knockdown might shed the light on the molecular mechanism 
for the observations in HAP1 knock-out mice which display impaired 
glucose tolerance [72].  
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4.2 Roles of HAP1 in the cell cycle 
 
The knockdown of HAP1 significantly reduced growth and affected the cell 
cycle of INS-1 cells. The decreased cell growth seemed not due to the 
induction of apoptosis, as there was neither apparent change of cells at 
sub-G1 phase nor the activation of caspase-3 which is the marker of 
apoptotic cell death. On the other hand, HAP1 knockdown significantly 
reduced cells in G1/G0 phase while increasing cells in G2/M phase, 
suggesting the occurrence of an arrest of cell cycle which might contribute 
to the slowed cell growth. 
 
It has been reported that HAP1 is involved in apoptosis. Takeshita found 
that, in spinal-and-bulbar-muscular-atrophy (SBMA), the apoptosis induced 
by the complex of mutant ARQ65 was suppressed by HAP1 co-transfection 
[64]. Thus, HAP1 may protect cells from apoptosis to some extent. 
Nevertheless, I did not observe obvious apoptosis of INS-1 cells after 
HAP1 knockdown. When caspase-3 activity was measured to check 
apoptosis at 48h and 72h, no significant difference was found between the 
control and knockdown cells. And, this result is consistent with my findings 
of flow cytometry, i.e. no significant increase of cells at the sub-G1 phase 
which reflects subdiploidy apoptosis after HAP1 knockdown in comparison 
with the control cells. What could be the reasonable explanation for this 
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discrepancy? First, Takeshita utilized a vivo mouse model, whereas I 
studied INS-1 cells which is a cell line derived from rat insulinoma. Second, 
a polyQ sequence derived from SBMA has an inclination to bind to HAP1 
[64]; however, the environment of INS-1 culture cannot provide such a 
complex condition.  
 
An interesting finding in my study is the observation of arrest of INS-1 cell 
cycle at G2/M phase after HAP1 knockdown, which could contribute to the 
decreased cell growth. Based on the measurements of DNA content, the 
number of INS-1 cells was decreased to 87% (48h) and 86% (72h) of 
control cells following HAP1 knockdown. Although the exact function of 
HAP1 in this scenario is still unclear, there is evidence that HAP1 plays a 
role in the intracellular vesicle trafficking. Two studies reported the 
implication of HAP1 in cell growth and division cycle. Li et al recently 
observed that HAP1 A was enriched in the growth cones and promoted 
neuritic development and synaptic function [94]. In addition, Martin et al.  
found that HAP1 was localized to the mitotic spindle apparatus, especially 
at spindle poles and on vesicles and microtubules of the spindle body [51]. 
Based on my results from flow cytometry analysis, HAP1 knockdown 
reduced cells at G1/G0 phase but increased cells in S and G2/M phases. 
This suggests that the G1 checkpoint for cell entry into cell cycle seems not 
involving HAP1. On the other hand, the increase of cells at G2/M phase 
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indicated an accumulation or arrest of cells in this stage, suggesting a role 




HAP1 Knockdown had two distinctive effects in INS-1 cells. First, it reduced 
glucose-stimulated insulin section by interfering with the step beyond 
[Ca2+]i rise in the secretion process cascade. Second, HAP1 knockdown 
slowed down the growth of INS-1 cells by arresting cell cycle possibly 
affecting the mitotic spindle assembly checkpoint but without induction of 
apparent apoptosis.  
 
4.4 Future works 
 
This study examined the potential role of HAP1 in the insulin-secreting INS-
1 cells and found that HAP1 might not only participate in glucose-
stimulated insulin secretion but also is involved in the control of cell cycle. 
To make those findings more convincing and understand the underlying 
mechanisms in more detail, further study should be explored. 
 
There are two HAP1 isoforms in rat and one in mouse; in human, the HAP1 
isoform shares great similarity with rat isoform A. While HAP1 B is 
distributed in the cytoplasm, HAP1 A is enriched in the growth cones and 
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has a function in neuritic development and synaptic function [94]. In my 
study, the INS-1 cell is derived from rat insulinoma, thus having two HAP1 
isoforms. To confirm whether HAP1 has similar function in a mouse model, 
some key experiments should be repeated in one of mouse insulin-
secreting cell lines, such as MIN6.  
 
In addition, INS-1 cell line is transformed from rat insulinoma and may be 
different from primary pancreatic β-cells in some properties [35]. With the 
development of the techniques in islet isolation, β-cell purification and its 
long-term culture in vitro, it is feasible that HAP1 function could be 
examined in the isolated primary β-cells by either transient or stable HAP1 
knockdown (e.g. using lentivirus-based transfection). This will make my 
findings in INS-1 cells more relevant to the physiological significance. In 
addition, it would be also interesting to assess if there is any change of 
HAP1 in diabetic animals.  
 
As mentioned in the introduction, the mouse model with Huntington’s 
disease was liable to develop T2DM [72]; HAP1 binds more tightly to 
mutant Huntingtin [94]. Moreover, when exposed to very high glucose 
(glucotoxicity), β-cells will exhibit some pathological reactions, such as 
altered glucose metabolism, enhanced basal insulin secretion, and reduced 
glucose-stimulated insulin secretion. Thus it is noteworthy to investigate the 
function of HAP1 in β-cells under the pathological conditions. 
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My study has revealed that HAP1 knockdown reduced glucose-stimulated 
insulin secretion in INS-1 cells by affecting the step beyond elevation of 
[Ca2+]i during secretory process. However, the exact action site and 
mechanism remain to be explored. The finding of HAP1 function in 
intracellular trafficking in the nervous system gave the hint for its potential 
role in the exocytosis of insulin granules. Thus some relevant experiments 
such as measurement of two-phase insulin secretion, and using patch 
clamp technique or permeabilized cells may be performed to address this 
issue.  
 
Finally, I found that HAP1 knockdown affected the cell cycle of INS-1 cells, 
potentially interfering with G2/M checkpoint. It is thus important to figure out 
what are the partners that HAP1 Interacts with (e.g. cyclins, CDKs and their 
inhibitors) and how it acts on them. Microarray study on cell growth and 
death may be carried out to study these questions initially to identify some 
candidates. In addition, the effect of HAP1 knockdown on cell growth 
seemed minor, perhaps due to the limited period of knockdown effects on 
cell cycle by using transient transfection of exogenous siRNA oligos which 
usually decrease in a few days. Therefore, to overcome this weakness, a 
stable cell line with HAP1 knockdown should be constructed to examine its 
function in cell growth.  
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